Diffuse Large B-Cell Lymphoma, NOS · line 2 · Lisocabtagene maraleucel (liso-cel) CAR-T 2L for primary-refractory or early-relapse LBCL (TRANSFORM)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REGIMEN-LISOCEL-DLBCL-2L |
| ID | IND-DLBCL-2L-LISOCEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 SRC-TRANSFORM-KAMDAR-2022 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L option for primary-refractory or early-relapse LBCL in transplant-intended patients per TRANSFORM phase 3. Eligibility narrower than 3L liso-cel (TRANSCEND ≥3L any-comer; separate IND-DLBCL-3L-LISO-CEL-CART entity). Trial source SRC-TRANSFORM-KAMDAR-2022 added to KB (HEME-1 C2, 2026-05-08); backfilled as primary source. PILOT cohort transplant-ineligible 2L expansion is separate future Indication entity. Axi-cel ZUMA-7 alternative 2L CAR-T not yet in KB as 2L Indication — author-later candidate.
Used By
Algorithms
ALGO-DLBCL-2L- ALGO-DLBCL-2L